Your browser doesn't support javascript.
loading
Case-Fatality and Functional Outcome after Subarachnoid Hemorrhage (SAH) in INternational STRoke oUtComes sTudy (INSTRUCT).
Rehman, Sabah; Phan, Hoang T; Reeves, Mathew J; Thrift, Amanda G; Cadilhac, Dominique A; Sturm, Jonathan; Breslin, Monique; Callisaya, Michele L; Vemmos, Konstantinos; Parmar, Priya; Krishnamurthi, Rita V; Barker-Collo, Suzanne; Feigin, Valery; Chausson, Nicolas; Olindo, Stephane; Cabral, Norberto L; Carolei, Antonio; Marini, Carmine; Degan, Diana; Sacco, Simona; Correia, Manuel; Appelros, Peter; Kõrv, Janika; Vibo, Riina; Minelli, Cesar; Sposato, Luciano; Pandian, Jeyaraj Durai; Kaur, Paramdeep; Azarpazhooh, M Reza; Morovatdar, Negar; Gall, Seana.
Afiliación
  • Rehman S; Menzies Institute for Medical Research, Hobart, Tasmania, University of Tasmania, Australia.
  • Phan HT; Menzies Institute for Medical Research, Hobart, Tasmania, University of Tasmania, Australia.
  • Reeves MJ; Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, USA.
  • Thrift AG; Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
  • Cadilhac DA; Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
  • Sturm J; Faculty of Health and Medicine, University of Newcastle, New South Wales, Australia.
  • Breslin M; Menzies Institute for Medical Research, Hobart, Tasmania, University of Tasmania, Australia.
  • Callisaya ML; Menzies Institute for Medical Research, Hobart, Tasmania, University of Tasmania, Australia; Struttura Complessa di Neurologia, Ospedale Michele e Pietro Ferrero, Verduno (Cuneo), ASL CN2, Italy.
  • Vemmos K; Hellenic Cardiovascular Research Society, Athens, Greece.
  • Parmar P; National Institute for Stroke and Applied Neurosciences, School of Clinical Sciences, Auckland University of Technology, Auckland, New Zealand.
  • Krishnamurthi RV; National Institute for Stroke and Applied Neurosciences, School of Clinical Sciences, Auckland University of Technology, Auckland, New Zealand.
  • Barker-Collo S; School of Psychology, University of Auckland, Auckland, New Zealand.
  • Feigin V; National Institute for Stroke and Applied Neurosciences, School of Clinical Sciences, Auckland University of Technology, Auckland, New Zealand.
  • Chausson N; Stroke Unit, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.
  • Olindo S; Stroke Unit, University Hospital of Bordeaux, Bordeaux, France.
  • Cabral NL; Deceased. Formerly Clinica Neurológica de Joinville, Joinville Stroke Registry, University of Joinville Region-Univille, Joinville, Brazil.
  • Carolei A; Department of Biotechnological and Applied Clinical Sciences, Neurological Institute, University of L'Aquila, Italy.
  • Marini C; Department of Life, Health, and Environmental Sciences, University of L'Aquila, Italy.
  • Degan D; Struttura Complessa di Neurologia, Ospedale Michele e Pietro Ferrero, Verduno (Cuneo), ASL CN2, Italy.
  • Sacco S; Department of Biotechnological and Applied Clinical Sciences, Neurological Institute, University of L'Aquila, Italy.
  • Correia M; Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Portugal.
  • Appelros P; Department of Neurology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Kõrv J; Department of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
  • Vibo R; Department of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
  • Minelli C; Hospital Carlos Fernando Malzoni and Neurologic Center of Research and Rehabilitation, Matão, SP, Brazil.
  • Sposato L; Department of Neurology, Western University, London, Ontario, Canada.
  • Pandian JD; Department of Neurology, Christian Medical College, Ludhiana, Punjab, India.
  • Kaur P; Department of Obstetrics & Gynaecology, University of British Columbia, Vancouver, Canada.
  • Azarpazhooh MR; Department of Clinical Neurological Sciences, University of Western, London, Ontario, Canada.
  • Morovatdar N; Clinical Research Development Unit, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Gall S; Menzies Institute for Medical Research, Hobart, Tasmania, University of Tasmania, Australia; Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. Electronic address: Seana.Gall@utas.edu.au.
J Stroke Cerebrovasc Dis ; 31(1): 106201, 2022 Jan.
Article en En | MEDLINE | ID: mdl-34794031
ABSTRACT

BACKGROUND:

There are few large population-based studies of outcomes after subarachnoid hemorrhage (SAH) than other stroke types.

METHODS:

We pooled data from 13 population-based stroke incidence studies (10 studies from the INternational STRroke oUtComes sTudy (INSTRUCT) and 3 new studies; N=657). Primary outcomes were case-fatality and functional outcome (modified Rankin scale score 3-5 [poor] vs. 0-2 [good]). Harmonized patient-level factors included age, sex, health behaviours (e.g. current smoking at baseline), comorbidities (e.g.history of hypertension), baseline stroke severity (e.g. NIHSS >7) and year of stroke. We estimated predictors of case-fatality and functional outcome using Poisson regression and generalized estimating equations using log-binomial models respectively at multiple timepoints.

RESULTS:

Case-fatality rate was 33% at 1 month, 43% at 1 year, and 47% at 5 years. Poor functional outcome was present in 27% of survivors at 1 month and 15% at 1 year. In multivariable analysis, predictors of death at 1-month were age (per decade increase MRR 1.14 [1.07-1.22]) and SAH severity (MRR 1.87 [1.50-2.33]); at 1 year were age (MRR 1.53 [1.34-1.56]), current smoking (MRR 1.82 [1.20-2.72]) and SAH severity (MRR 3.00 [2.06-4.33]) and; at 5 years were age (MRR 1.63 [1.45-1.84]), current smoking (MRR 2.29 [1.54-3.46]) and severity of SAH (MRR 2.10 [1.44-3.05]). Predictors of poor functional outcome at 1 month were age (per decade increase RR 1.32 [1.11-1.56]) and SAH severity (RR 1.85 [1.06-3.23]), and SAH severity (RR 7.09 [3.17-15.85]) at 1 year.

CONCLUSION:

Although age is a non-modifiable risk factor for poor outcomes after SAH, however, severity of SAH and smoking are potential targets to improve the outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hemorragia Subaracnoidea / Trastornos Cerebrovasculares / Accidente Cerebrovascular Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Stroke Cerebrovasc Dis Asunto de la revista: ANGIOLOGIA / CEREBRO Año: 2022 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hemorragia Subaracnoidea / Trastornos Cerebrovasculares / Accidente Cerebrovascular Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Stroke Cerebrovasc Dis Asunto de la revista: ANGIOLOGIA / CEREBRO Año: 2022 Tipo del documento: Article País de afiliación: Australia